The claimed group of inventions relates to the field of medicine, in particular, to pharmacology. The novel dosage form is characterized by the neutral carrier thereof that does not contain chemical, plant-based, or biological compounds - the substances causing side effects and having contraindications to the administration thereof. The dosage form is a neutral carrier with low intensity energy-informational electromagnetic radiation transmitted thereupon from a parent chemical or biological substance, which produces the desired pharmacological effect. The neutral carrier is a liquid (water, aqueous medium), patch, gel, or suspension. The method for the preparation of the dosage form includes transmission of low intensity energy-informational electromagnetic radiation bearing the desired pharmacological effect of the parent chemical, plant-based, or biological substance onto a neutral carrier suitable for interaction with the patients body. The low intensity energy-informational electromagnetic radiation is transferred onto the neutral carrier from an intermediate carrier, which is suitable for the storage and transmission of low intensity energy-informational electromagnetic signals. The transmission of radiation is previously conducted onto one intermediate carrier the radiation is wirelessly transmitted through communication media to a second intermediate carrier (optical disc), upon which the neutral carrier is exposed. The neutral carrier exposed on the intermediate carrier is an aqueous medium, such as potable water or saline solution. The result is improved safety, expanded range of the drug use, and elimination of side effects during treatment due to elimination of the direct chemical or pathophysiological effect on the patients body while using the claimed dosage form, which reproduces main therapeutic properties of the chemical or biological drug
